BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Search
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
STING agonist (2nd generation)
Second generation STING agonist
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Sales consultant about working with purpose
Bok talks about how he found purpose in his career. After his father was diagnosed with cancer, he decided to work as an oncology sales consultant.
Animal Health Partnering Interests Oncology May 2024 CORP
oncology_flyer_bio_05-2020.pdf
Nintedanib_in_Oncology_Backgrounder.pdf
Oncology_Flyer_BIO_2022.pdf
Partnering_In_Oncology_0422.pdf
Partnering_In_ONCOLOGY_0.pdf
Partnering in Oncology MAY 2024 CORP .pdf
Partnering in Oncology MAY 2024 CORP_0.pdf
Partnering in Oncology JAN 2023 Corporate
Partnering in Oncology JAN 2023 Corporate
bi_in_oncology_backgrounder.pdf
bi_oncology_backgrounder3.0_approved.pdf
Oncology_Partnering_Interests-2018-12.pdf
Oncology_Backgrounder_05_2016.PDF
2015 09 18 BI in Oncology Backgrounder_6.0_ohne694.pdf
Modified yersinia
Modified yersinia
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
VSV-GP
VSV-GP